货号:A225129
同义名:
Lycoricidinol; (+)-Narciclasine
Narciclasine是一种植物生长调节剂。Narciclasine调节Rho/Rho激酶/LIM激酶/cofilin信号通路,显著增加RhoA的GTP酶活性,并依赖RhoA诱导肌动蛋白应力纤维的形成。
HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Cdc42-subclass ↓ ↑ | Rac ↓ ↑ | Rho-subclass ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZCL278 |
++
Cdc42 GTPase, Kd: 11.4 μM |
98% | |||||||||||||||||
| ML141 |
+++
cdc42, IC50: 200 nM |
99%+ | |||||||||||||||||
| NSC 23766 3HCl |
+
Rac GTPase, IC50: 50 μM |
98% | |||||||||||||||||
| EHop-016 |
+++
Rac1, IC50: 1.1 μM |
98% | |||||||||||||||||
| Azathioprine | ✔ | 98% | |||||||||||||||||
| EHT 1864 |
++++
Rac3, Kd: 50 nM Rac1, Kd: 40 nM |
99%+ | |||||||||||||||||
| Zoledronic Acid | ✔ | Ras | 98% | ||||||||||||||||
| CCG-1423 | ✔ | 99%+ | |||||||||||||||||
| CCG-203971 | ✔ | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | ROCK ↓ ↑ | ROCK1 ↓ ↑ | ROCK2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thiazovivin |
+
ROCK, IC50: ~0.5 μM |
98% | |||||||||||||||||
| Netarsudil HCl |
++++
ROCK, Ki: 2 nM |
99%+ | |||||||||||||||||
| Y-33075 2HCl |
++++
ROCK, IC50: 3.6 nM |
99%+ | |||||||||||||||||
| ROCK1-IN-1 |
++
ROCK, Ki: 17nM |
95% | |||||||||||||||||
| GSK429286A |
+++
ROCK1, IC50: 14 nM |
++
ROCK2, IC50: 63 nM |
99%+ | ||||||||||||||||
| Ripasudil |
++
ROCK1, IC50: 51 nM |
++
ROCK2, IC50: 19 nM |
99%+ | ||||||||||||||||
| Belumosudil |
++
ROCK2, Ki: 41 nM ROCK2, IC50: 60 nM |
99%+ | |||||||||||||||||
| Y-27632 2HCl |
++
ROCK1, Ki: 140 nM |
+
ROCK2, Ki: 300 nM |
99%+ | ||||||||||||||||
| Fasudil HCl |
+
ROCK2, Ki: 330 nM |
Rho,PKG | 98% | ||||||||||||||||
| Chroman 1 |
++++
ROCK1, IC50: 52 pM |
++++
ROCK2, IC50: 1 pM |
99% | ||||||||||||||||
| BAY-549 |
++++
ROCK1, IC50: 0.6 nM |
++++
ROCK2, IC50: 1.1 nM |
99%+ | ||||||||||||||||
| AT13148 |
+++
ROCK1, IC50: 6 nM |
+++
ROCK2, IC50: 4 nM |
PKA | 95% | |||||||||||||||
| RKI-1447 |
+++
ROCK1, IC50: 14.5 nM |
+++
ROCK2, IC50: 6.2 nM |
99%+ | ||||||||||||||||
| Hydroxyfasudil HCl |
+
ROCK1, IC50: 0.73 μM |
+
ROCK2, IC50: 0.72 μM |
PKA | 98% | |||||||||||||||
| H-1152 2HCl |
+++
ROCK2, IC50: 0.0120 μM |
PKG | 99% | ||||||||||||||||
| GSK269962A HCl |
++++
ROCK1, IC50: 1.6 nM |
+++
ROCK2, IC50: 4 nM |
99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Narciclasine triggers activation of Rho and stress fibers within glioblastoma multiforme (GBM) cells, exhibiting a mean IC50 of approximately 50 nM across six human GBM cell lines (U373, Hs683, GL19, GL5, GL16, GL17), which also demonstrates a mean IC50 value of 47 nM against a diverse array of 60 cancer cell lines[1]. Further exploration through bioassay-guided fractionation of A. belladonna extract pinpointed lycorine as the active compound, with Narciclasine showing a significant IC50 of 0.1 μM for radicle growth inhibition[2]. |
| 体内研究 | In vivo studies reveal that an intravenous (i.v.) administration of Narciclasine at 1 mg/kg significantly enhances the survival rates of mice bearing GL19 GBM (P=0.02). Similarly, oral administration of Narciclasine at the same dosage, five times weekly for five weeks, markedly prolongs survival in this model (P=0.008). Oral treatment at 1 mg/kg also significantly boosts survival (P=0.004) in mice with Hs683 GBM, with no added survival benefit from increasing the dosage frequency. Narciclasine showcases efficacy comparable to that of temozolomide in these models, but at significantly lower doses and through both oral and i.v. routes[1]. |
| 体外研究 | Narciclasine triggers activation of Rho and stress fibers within glioblastoma multiforme (GBM) cells, exhibiting a mean IC50 of approximately 50 nM across six human GBM cell lines (U373, Hs683, GL19, GL5, GL16, GL17), which also demonstrates a mean IC50 value of 47 nM against a diverse array of 60 cancer cell lines[1]. Further exploration through bioassay-guided fractionation of A. belladonna extract pinpointed lycorine as the active compound, with Narciclasine showing a significant IC50 of 0.1 μM for radicle growth inhibition[2]. |
| Concentration | Treated Time | Description | References | |
| Yeast strain SAN006 | 0.1 mM | Assess cytotoxicity of sanguinarine | Genes Dis. 2023 Apr 13;11(5):100938. | |
| MDA-MB-231 breast cancer cells | 1 µM | 24 hours | Induced DNA laddering | Neoplasia. 2007 Sep;9(9):766-76. |
| CoN | 1.1 µM (IC50) | 72 hours | Inhibited cell proliferation with IC50 of 1.1 μM | Biomolecules. 2022 Sep 9;12(9):1267. |
| DLD-1 | 0.030 µM (IC50) | 72 hours | Inhibited cell proliferation with IC50 of 0.030 μM | Biomolecules. 2022 Sep 9;12(9):1267. |
| HCT-116 | 0.052 µM (IC50) | 72 hours | Inhibited cell proliferation with IC50 of 0.052 μM | Biomolecules. 2022 Sep 9;12(9):1267. |
| HT-29 | 0.032 µM (IC50) | 72 hours | Inhibited cell proliferation with IC50 of 0.032 μM | Biomolecules. 2022 Sep 9;12(9):1267. |
| LoVo | 0.023 µM (IC50) | 72 hours | Inhibited cell proliferation with IC50 of 0.023 μM | Biomolecules. 2022 Sep 9;12(9):1267. |
| Ccd-25-Lu normal lung fibroblasts | 1 µM | 18 hours | No marked apoptotic morphological changes induced | Neoplasia. 2007 Sep;9(9):766-76. |
| PC-3 prostate cancer cells | 1 µM | 18 hours | Induced marked apoptotic morphological changes and loss of mitochondrial membrane potential | Neoplasia. 2007 Sep;9(9):766-76. |
| MCF-7 breast cancer cells | 1 µM | 18 hours | Induced marked apoptotic morphological changes and loss of mitochondrial membrane potential | Neoplasia. 2007 Sep;9(9):766-76. |
| Tobacco BY-2 cells | 0.5 and 5.0 µM | 2 days | To study the effects of NCS on cell cycle progression, results showed that NCS inhibits cell division and affects the expression of cell cycle genes. | BMC Plant Biol. 2011 Dec 28;11:184. |
| HCC-1937 | 50 nM | 24 hours | To evaluate the inhibitory effect of Narciclasine on HCC-1937 cell proliferation and its ability to induce autophagy-dependent apoptosis | Cell Prolif. 2018 Dec;51(6):e12518. |
| MCF-7/TR cells | 100 nM | 24 hours | Specifically degraded total STAT3 via the proteasome pathway | Mol Ther Oncolytics. 2022 Jan 3;24:340-354. |
| MCF-7 cells | 100 nM | 24 hours | Suppressed phosphorylation, activation, dimerization, and nuclear translocation of STAT3 | Mol Ther Oncolytics. 2022 Jan 3;24:340-354. |
| IMG cells | 50 nM | 24 hours | To evaluate the effect of Narciclasine on LPS-induced inflammatory response. Results showed that Narciclasine alone did not induce inflammatory response but exacerbated inflammation when combined with LPS. | Cells. 2023 May 11;12(10):1367. |
| BSC-1 cells | 40-320 nM | 24 hours | To evaluate the inhibitory effect of Narciclasine on VACV viral protein expression in BSC-1 cells, showing a dose-dependent decrease in viral protein levels. | Biosaf Health. 2024 Nov 19;6(6):341-349. |
| Huh7.5.1 cells | 40-320 nM | 24 hours | To evaluate the cytotoxicity of Narciclasine on Huh7.5.1 cells, showing a slight reduction in cell viability starting from 80 nM. | Biosaf Health. 2024 Nov 19;6(6):341-349. |
| HeLa cells | 40-320 nM | 24 hours | To evaluate the cytotoxicity of Narciclasine on HeLa cells, showing no significant effect on cell viability at ≤320 nM. | Biosaf Health. 2024 Nov 19;6(6):341-349. |
| 36C15Q cells | 20 nM | 48 hours | Promotes oxidative metabolism gene expression, reduces lipid accumulation | PLoS Biol. 2017 Feb 16;15(2):e1002597. |
| C2C12 cells | 20 nM | 48 hours | Promotes oxidative metabolism gene expression, reduces lipid accumulation | PLoS Biol. 2017 Feb 16;15(2):e1002597. |
| Arabidopsis root tip cells | 0.5 and 5.0 µM | 6 to 48 hours | To analyze the effects of NCS on the expression of core cell cycle genes, results showed that NCS disturbs the expression of G1/S and G2/M phase genes. | BMC Plant Biol. 2011 Dec 28;11:184. |
| Neonatal rat cardiomyocytes (NRCMs) | 0, 30, 100, and 300 nM | To evaluate the effect of Narciclasine on LPS-induced inflammation in cardiomyocytes. Results showed that Narciclasine attenuated LPS-induced decrease in cell viability in a dose-dependent manner, suppressed inflammatory cytokine (TNF-α, IL-1β, and IL-6) release, and reduced apoptosis. | Aging (Albany NY). 2021 May 25;13(11):15151-15163. | |
| Administration | Dosage | Frequency | Description | References | ||
| C57BL/6 mice | LPS-induced acute myocardial injury model | Gavage | 0.1 mg/kg | Once daily for 7 days | To investigate the protective effect of Narciclasine on LPS-induced myocardial injury. Results showed that Narciclasine partly improved cardiac function parameters (e.g., LVEF and LVFS), increased survival rates, and reduced inflammatory indicators (e.g., MPO and cytokines IL-6, IL-1β, TNF-α, VEGF). | Aging (Albany NY). 2021 May 25;13(11):15151-15163. |
| Neonatal rats | E. coli-induced sepsis model | Intraperitoneal injection | 0.1 mg/kg, 1 mg/kg, 3 mg/kg | Administered 1 hour after sepsis induction, observed for 30 hours | Narciclasine significantly reduced mortality in neonatal rats with sepsis, alleviated clinical sepsis symptoms, reduced bacterial load, decreased levels of inflammatory cytokines, inhibited the expression of S100A8/A9, alleviated inflammation and injury in liver and lungs, improved hematological parameters, and suppressed the activation of the NF-κB signaling pathway. | Sci Rep. 2020 Feb 19;10(1):2947 |
| Arabidopsis | Arabidopsis seedlings | Medium treatment | 0.1, 0.5, 1.0 and 5.0 μM | Continuous treatment for 7 days | To study the inhibitory effects of NCS on Arabidopsis root growth, results showed that NCS significantly inhibited root growth and lateral root density. | BMC Plant Biol. 2011 Dec 28;11:184. |
| Sprague-Dawley rats | LPS-induced neonatal acute lung injury model | Subcutaneous injection | 0.7 mg/kg | Administered 12 hours prior to LPS exposure, lasting for 72 hours | Narciclasine attenuated LPS-induced pathological injury and pulmonary edema, suppressed the secretion of inflammatory cytokines, alleviated oxidative stress and apoptosis, and exerted protective effects by inhibiting the activation of the TLR4/NF-κB/Cox2 signaling pathway. | Bioengineered. 2020 Dec;11(1):801-810 |
| Mice | High-fat diet-induced obesity model | Oral gavage | 1 mg/kg | Weekly for seven consecutive weeks | Attenuates obesity, promotes energy expenditure, improves metabolic parameters | PLoS Biol. 2017 Feb 16;15(2):e1002597. |
| BALB/c-nu mice | MCF-7 xenograft model | Intraperitoneal injection | 1 mg/kg | Every 2 days for 4 weeks | Significantly reduced tumor size and weight, decreased STAT3 phosphorylation levels | Mol Ther Oncolytics. 2022 Jan 3;24:340-354. |
| BALB/c nude mice | HCC1937 TNBC xenograft model | Oral | 2 or 5 mg/kg | Three times per week for 21 days | To evaluate the inhibitory effect of Narciclasine on HCC1937 TNBC xenograft tumor growth and its mechanism | Cell Prolif. 2018 Dec;51(6):e12518. |
| BALB/C mice | IMQ-induced psoriasis-like dermatitis model | Intradermal injection | 2mg/kg | Once daily for 6 days | To evaluate the therapeutic effect of Ncs on IMQ-induced psoriasis-like dermatitis, results showed that Ncs significantly improved skin lesions, reduced epidermal thickening and immune cell infiltration. | Front Immunol. 2023 Jan 4;13:1094375 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.25mL 0.65mL 0.33mL |
16.27mL 3.25mL 1.63mL |
32.55mL 6.51mL 3.25mL |
|
| CAS号 | 29477-83-6 |
| 分子式 | C14H13NO7 |
| 分子量 | 307.26 |
| SMILES Code | O=C1N[C@@]2([H])[C@H](O)[C@H](O)[C@@H](O)C=C2C3=C1C(O)=C4C(OCO4)=C3 |
| MDL No. | MFCD01729949 |
| 别名 | Lycoricidinol; (+)-Narciclasine; NSC 266535; Lycoricidin-A; Lycorcidinol; (+)-Lycoricidinol |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 25 mg/mL(81.37 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1